# Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

> **NCT04650451** · PHASE1 · SUSPENDED · sponsor: **Bellicum Pharmaceuticals** · enrollment: 220 (estimated)

## Conditions studied

- HER-2 Gene Amplification
- HER2-positive Gastric Cancer
- HER2-positive Breast Cancer
- HER-2 Protein Overexpression
- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** chimeric antigen receptor (CAR) T cell therapy

## Key facts

- **NCT ID:** NCT04650451
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-12-07
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-01-02
- **Target enrollment:** 220 (ESTIMATED)
- **Why stopped:** Due to a Dose Limiting Toxicity in another sister trial with same technology.
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04650451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04650451, "Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04650451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*